1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,220 | 1,240 | 18.10. | |
| 0,000 | 0,000 | 16.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.10. | NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 | 1.095 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("the Company") is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd... ► Artikel lesen | |
| 29.09. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 29.09. | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials | 823 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June... ► Artikel lesen | |
| 28.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 28.09. | Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricides | 553 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 23.09. | Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox Has Begun in DRC, Announces NanoViricides | 877 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral... ► Artikel lesen | |
| 15.09. | NanoViricides, Inc.: Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides | 1.248 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 08.09. | NanoViricides: Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo | 1.093 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 31.08. | While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles | 818 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 18.08. | NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon | 1.295 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 10.08. | NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak | 10.958 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 30.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 9 | SEC Filings | ||
| 28.07. | NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial | 9.247 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 24.07. | NanoViricides announces $3.8M registered direct offering; shares down | 5 | Seeking Alpha | ||
| 24.07. | NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering | 1.566 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 22.07. | As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola | 8.967 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 17.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.07. | As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo | 812 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 08.07. | Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | 907 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a... ► Artikel lesen | |
| 06.07. | Noble Capital startet Coverage für NanoViricides mit "Outperform" | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 19,680 | -0,40 % | EQS-News: Formycon AG: Formycon und Zydus: FDA nimmt FYB206 als erstes öffentlich bekannt gegebenes Keytruda-Biosimilar zur Prüfung an | EQS-News: Formycon AG
/ Schlagwort(e): Zulassungsantrag
Formycon und Zydus: FDA nimmt FYB206 als erstes öffentlich bekannt gegebenes Keytruda-Biosimilar zur Prüfung an
13.10.2026... ► Artikel lesen | |
| ONTO INNOVATION | 195,05 | -0,66 % | Will Onto Innovation's Cash Balance Fuel Its Next Growth Phase? | ||
| GOMSPACE | 1,221 | +2,52 % | GomSpace A/S: GomSpace Launches GOMX-5 to Demonstrate Next-Generation Satellite Communications Technologies | The ESA-supported mission validates next-generation communications technologies in orbit, strengthens GomSpace's flight heritage, and supports future commercial... ► Artikel lesen | |
| RIBER | 6,580 | 0,00 % | Riber Reports Improved Results For The First Half Of 2026 | RIBER REPORTS IMPROVED RESULTS FOR THE FIRST HALF OF 2026 Revenues of €12.7m (+19%) and gross margin of €5.1m (+31%), representing 39.8% of revenuesPositive net income of €0.2m, compared with -€0.8m... ► Artikel lesen | |
| KOPIN | 2,899 | -0,82 % | Fabric.AI (Nasdaq: FABC) Stockholders Ratify Kopin Strategic Partnership to Develop Neural I/o MicroLED Optical Interconnect Technology for Next Generation AI Data Centers | NEW YORK, NY, June 24, 2026 (GLOBE NEWSWIRE) -- Fabric.AI, Inc. (Nasdaq: FABC) ("Fabric.AI" or the "Company"), a fabless semiconductor company developing MicroLED-based optical interconnects for AI... ► Artikel lesen | |
| CALIFORNIA NANOTECHNOLOGIES | 0,253 | +11,95 % | California Nanotechnologies Corp.: California Nanotechnologies to Present at the Planet MicroCap Showcase: Toronto in Partnership with MicroCapClub on Wednesday, October 28, 2026 | Los Angeles, California--(Newsfile Corp. - October 14, 2026) - California Nanotechnologies Corp. (TSXV: CNO) (OTCID: CANOF) ("Cal Nano" or the "Company") is pleased to announce today announced that... ► Artikel lesen | |
| OBDUCAT | 0,028 | 0,00 % | NGM MARKET NOTICE: #26-72 Decision by the Disciplinary Committee regarding Obducat AB (publ) | ||
| GAUZY | 4,530 | -0,44 % | Investors headed by CEO injecting $7m into Gauzy | ||
| SOLESENCE | 0,900 | 0,00 % | Solésence, Inc.: Solésence Reports Second Quarter 2026 Financial Results | Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically... ► Artikel lesen | |
| ACACIA RESEARCH | 3,720 | -0,53 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,314 | +3,97 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| LAMPETIA | 0,135 | 0,00 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| DOTZ NANO | 0,007 | +25,86 % | DOTZ NANO LIMITED: Change of CFO | ||
| ANTEOTECH | 0,007 | 0,00 % | ANTEOTECH LTD: AnteoTech Company Presentation - The Battery Show | ||
| ZENTEK | 0,376 | -2,08 % | Zentek Ltd.: Zentek Announces New Additions to Team and Management Change | Guelph, Ontario--(Newsfile Corp. - October 5, 2026) - Zentek Ltd. (TSXV: ZEN) (OTCQX: ZTEKF) ("Zentek" or the "Company") announces two additions to its team to support the commercialization of ZenGUARD... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Mit einer aktuellen Kursveränderung von -0,040 (-3,39 %) liegt der Kurs bei 1,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.